Cargando…
DNMT Inhibitors Increase Methylation in the Cancer Genome
DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved therapies for myelodysplastic syndrome and acute myeloid leukemia, and their combinations with other anticancer agents are being tested as therapeutic options for multiple solid cancers such as colon, ovarian, and lung...
Autores principales: | Giri, Anil K., Aittokallio, Tero |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491738/ https://www.ncbi.nlm.nih.gov/pubmed/31068808 http://dx.doi.org/10.3389/fphar.2019.00385 |
Ejemplares similares
-
What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015) -
Target-specific compound selectivity for multi-target drug discovery and repurposing
por: Wang, Tianduanyi, et al.
Publicado: (2022) -
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
por: Ianevski, Aleksandr, et al.
Publicado: (2020) -
Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data
por: Ianevski, Aleksandr, et al.
Publicado: (2022) -
SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples
por: Ianevski, Aleksandr, et al.
Publicado: (2022)